Gastroenterology · Ulcerative ColitisTrial Updateclinicalmid-term

AbbVie initiates pediatric study of Risankizumab for Ulcerative Colitis

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AbbVie9 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/25/2026, 12:31:19 PM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The initiation of a pediatric study for Risankizumab by AbbVie is significant as it expands their portfolio in a critical therapeutic area, potentially enhancing their competitive edge in the pediatric gastroenterology market. Successful outcomes could lead to increased market share and improved treatment options for young patients with Ulcerative Colitis. Regulatory context from FDA (FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes) supports the near-term read.

Strategic Assessment

Portfolio teams should monitor the trial's progress as successful outcomes could enhance AbbVie's positioning in pediatric UC treatments. The strongest clinical anchor is A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis (ClinicalTrials.gov), entity match (abbvie); patient population match (pediatric). In Gastroenterology · Ulcerative Colitis, 7 regulatory and 4 competitive items passed relevance filtering for AbbVie.

Competitive Pressure

The most relevant competitive pressure comes from Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This trial expands AbbVie's portfolio in pediatric gastroenterology, potentially increasing market share against competitors in the UC space.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes (FDA). Entity match (pediatric patients); Patient population match (pediatric). The outcomes of this trial could influence future labeling and approval processes for Risankizumab in pediatric populations, potentially leading to expanded indications and market access.

Key Risks

Elevated medium regulatory exposure for AbbVie could delay market entry or constrain labeling if agency review intensifies.
Competitive risk from Humanexa Signals (V116 shows safety and immunogenicity in high-risk children for pneumococcal disease) could weigh on AbbVie through competitive crowding and share erosion if follow-through weakens.

Key Opportunities

If the trial demonstrates positive results, AbbVie could capture a larger share of the pediatric UC market, impacting revenue positively as they position Risankizumab as a preferred treatment option.
Portfolio teams should monitor the trial's progress as successful outcomes could enhance AbbVie's positioning in pediatric UC treatments.

What Would Change This Assessment

This becomes more urgent if Key milestones include enrollment completion, interim results from the induction phase, and safety data from the maintenance phase.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Entity match (pediatric patients); Patient population match (pediatric)
FDA document
View source
FDA Approves Drug for Pediatric Stage 3 Type I Diabetes
FDAhigh relevance
Entity match (pediatric patients); Patient population match (pediatric)
FDA document
View source
FDA AP — MALARONE PEDIATRIC (SUPPL)
FDAhigh relevance
Patient population match (pediatric); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Patient population match (pediatric); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Patient population match (pediatric); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Patient population match (pediatric); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Patient population match (pediatric); Regulatory pathway relevance (nda)
FDA document
View source

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
ClinicalTrials.govhigh relevance
Entity match (abbvie); Patient population match (pediatric)
FDA document
View source
Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
V116 shows safety and immunogenicity in high-risk children for pneumococcal disease
Humanexa Signalsmedium relevance
Patient population match (pediatric)
UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AbbVie
Risankizumab
pediatric patients

Commercial impact

medium

If the trial demonstrates positive results, AbbVie could capture a larger share of the pediatric UC market, impacting revenue positively as they position Risankizumab as a preferred treatment option.

Regulatory impact

medium

The outcomes of this trial could influence future labeling and approval processes for Risankizumab in pediatric populations, potentially leading to expanded indications and market access.

What to watch

Key milestones include enrollment completion, interim results from the induction phase, and safety data from the maintenance phase.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.